Insider Buying at MIRA Pharmaceuticals as Matthew Del Giudice Acquires Shares
Matthew Del Giudice purchased 50,000 shares of MIRA Pharmaceuticals on June 12, 2026.
Key Points
- Matthew Del Giudice bought 50,000 shares of MIRA Pharmaceuticals on June 12, 2026, with the stock trading around $0.93.
- MIRA Pharmaceuticals has a market cap of about $39.2 million and trades between $0.90 and $2.45 over the past year.
- Other insiders, including CEO Erez Aminov, also made recent purchases, reflecting internal confidence in the company.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Matthew Del Giudice, an insider at MIRA Pharmaceuticals, Inc. (NasdaqCM: MIRA), purchased 50,000 shares of the company on June 12, 2026. This transaction comes as the stock is trading near $0.93. The purchase highlights insider interest in the company's future prospects.
Insider Buying and Selling at MIRA Pharmaceuticals, Inc.
On June 12, 2026, several insiders, including Matthew Del Giudice, Edward Clouston Macpherson, Matthew Pratt Whalen, and Denil Nanji Shekhat, each bought 50,000 shares of MIRA Pharmaceuticals. These transactions were not part of a pre-planned trading scheme. Earlier, on December 17, 2025, CEO Erez Aminov acquired 3,155,170 shares, indicating strong insider confidence in the company's direction.
Other Institutional Activity in MIRA Pharmaceuticals
Vanguard Capital Management LLC increased its position in MIRA Pharmaceuticals by acquiring 693,912 shares, bringing its total to 693,912 shares, valued at approximately $742,486. Geode Capital Management, LLC also boosted its holdings, adding 18,012 shares to end with 290,890 shares worth about $311,251. In contrast, Suncoast Equity Management reduced its position by 12,644 shares, leaving it with 90,645 shares valued at $96,990.
MIRA Pharmaceuticals, Inc. Stock Up 24.2%
Shares of NasdaqCM:MIRA traded around $0.93 recently. The company has a market cap of approximately $39.2 million. MIRA Pharmaceuticals is not currently profitable, thus it has no meaningful P/E ratio. The stock's 52-week range is between $0.90 and $2.45, with a 50-day moving average of $1.02 and a 200-day moving average of $1.28. The firm's current ratio is exceptionally high at 82.16, which indicates strong liquidity.
About MIRA Pharmaceuticals
MIRA Pharmaceuticals, Inc. is a healthcare company based in Miami, Florida, focusing on developing treatments for neurological and neuropsychiatric disorders. The company is working on several pre-clinical and clinical-stage products, including Ketamir-2, an NMDA receptor modulator, and MIRA-55, an investigational treatment for anxiety and cognitive decline. Led by CEO Erez Aminov, MIRA Pharmaceuticals aims to advance its pipeline to address unmet medical needs in neuroscience.
Bottom Line
Insider buying activity at MIRA Pharmaceuticals, particularly by key figures like CEO Erez Aminov and other insiders, suggests confidence in the company's future. While the latest 13F filings provide a historical snapshot, these insider transactions may offer insights into potential future developments. Investors often watch such moves closely, as they can signal insiders' expectations for the company's performance.
Get MIRA Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $MIRA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.